icrucumab

{
  "id": "MLC-T-ONC-014304",
  "term": "icrucumab",
  "field": "Oncology and biomedicine",
  "definition": "A fully human IgG1 monoclonal antibody directed against human vascular endothelial growth factor receptor 1 (VEGFR-1/FLT-1) with potential antiangiogenesis and antineoplastic activities. Icrucumab specifically binds to and inhibits the activity of VEGFR-1, which may prevent the activation of downstream signaling pathways and so inhibit tumor angiogenesis; the subsequent reduction in tumor nutrient supply may inhibit tumor cell proliferation. Tumor cell overexpression of VEGFR-1 may be associated with tumor angiogenesis and tumor cell proliferation and invasion; VEGFR-1 may modulate VEGFR-2 signaling.",
  "synonyms": [
    "anti-vascular endothelial growth factor receptor-1 monoclonal antibody IMC-18F1",
    "anti-VEGFR-1 monoclonal antibody IMC-18F1"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/icrucumab/"
}